Cohort, n
|
BGS
|
230
|
230
|
CLUE II
|
87
|
87
|
CSB
|
69
|
69
|
Guernsey
|
124
|
124
|
NHS
|
93
|
93
|
NHS II
|
248
|
250
|
NSMSC
|
31
|
31
|
NYUWHS
|
493
|
496
|
ORDET
|
214
|
224
|
Sister
|
173
|
286
|
Age at blood donation, years, n (%)
|
35–40
|
472 (26.8)
|
487 (25.8)
|
41–45
|
708 (40.2)
|
752 (39.8)
|
46–50a
|
582 (33.0)
|
651 (34.5)
|
Race/ethnicity, n (%)
|
White
|
1587 (90.1)
|
1696 (89.7)
|
Black/African American
|
76 (4.3)
|
73 (3.9)
|
Other or missing
|
99 (5.6)
|
121 (6.4)
|
Age at diagnosis, years, n (%)
|
35–45
|
287 (16.3)
| |
46–50
|
579 (32.9)
| |
51–55
|
436 (24.7)
| |
56–60
|
235 (13.3)
| |
61–65
|
141 (8.0)
| |
> 65
|
84 (4.8)
| |
Lag time between blood donation and diagnosis, years, n (%)
|
0–2
|
274 (15.6)
| |
3–5
|
420 (23.8)
| |
6–10
|
443 (25.1)
| |
11–15
|
286 (16.2)
| |
16–20
|
201 (11.4)
| |
> 20
|
138 (7.8)
| |
Age at menarche, years, n (%)
|
< 12
|
376 (21.3)
|
411 (21.7)
|
12–13
|
976 (55.4)
|
1012 (53.5)
|
≥14 or missingb
|
410 (23.3)
|
467 (24.7)
|
Age at first live birth, years, n (%)
|
< 20 or missingb
|
114 (6.5)
|
143 (7.6)
|
20–24
|
457 (25.9)
|
521 (27.6)
|
25–29c
|
473 (26.8)
|
511 (27.1)
|
≥ 30
|
304 (17.3)
|
307 (16.2)
|
Nulliparous
|
414 (23.5)
|
408 (21.5)
|
Number of benign breast biopsies, n (%)
|
0 or missingb
|
1339 (76.0)
|
1559 (82.5)
|
≥ 1
|
423 (24.0)
|
331 (17.5)
|
0
|
1311 (74.4)
|
1415 (74.9)
|
1d
|
382 (21.7)
|
412 (21.8)
|
> 1d
|
69 (3.9)
|
63 (3.3)
|
BMI, kg/m2, n (%)
|
< 25
|
1097 (59.9)
|
1124 (62.6)
|
25–29
|
420 (24.8)
|
465 (24.0)
|
≥ 30
|
234 (15.4)
|
289 (13.4)
|
Missing
|
11
|
12
|
AMH cohort-specific quartiles, n(%)
|
Q1
|
365 (20.7)
|
480 (25.4)
|
Q2
|
444 (25.1)
|
468 (24.8)
|
Q3
|
453 (25.7)
|
468 (24.8)
|
Q4
|
500 (28.4)
|
474 (25.1)
|
Testosterone cohort-specific quartiles, n (%)
|
Q1
|
423 (24.0)
|
511 (27.0)
|
Q2
|
414 (23.5)
|
464 (24.6)
|
Q3
|
452 (25.7)
|
460 (24.3)
|
Q4
|
473 (26.8)
|
455 (24.1)
|
BCRAT 5-year risk score (%), n (%)e
|
< 0.6%
|
296 (16.8)
|
332 (17.6)
|
0.6–0.99%
|
679 (38.5)
|
765 (40.5)
|
1–1.66%
|
525 (29.8)
|
517 (27.3)
|
1.67–1.99%
|
110 (6.2)
|
130 (6.9)
|
2–2.99%
|
115 (6.5)
|
115 (6.1)
|
≥ 3%
|
37 (2.1)
|
31 (1.6)
|
ER status, n (%)
|
ER-positive
|
1139 (79.8)
| |
ER-negative
|
289 (20.2)
| |
Unknown
|
334
| |